Norihiro Ashihara Koji Nakajima Yoshiyuki Nakamura Mutsuhiro Kobayashi Kumiko Shirahata Chika Maeda Takeshi Uehara Daisuke Gomi Nobuo Ito
10.2169/internalmedicine.55.7134
Intern Med
2016;55(23):3453-3457.
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/27904108/
Bone Density Conservation Agents / therapeutic use Denosumab / therapeutic use Hypercalcemia / blood Hypercalcemia / drug therapy Paraneoplastic Syndromes / blood Paraneoplastic Syndromes / drug therapy
Bone Density Conservation Agents / therapeutic use Denosumab / therapeutic use Hypercalcemia / blood Hypercalcemia / drug therapy Paraneoplastic Syndromes / blood Paraneoplastic Syndromes / drug therapy Case Reports Bile Duct Neoplasms / complications Calcium / blood Cholangiocarcinoma / complications Humans Hypercalcemia / etiology Male Middle Aged Paraneoplastic Syndromes / etiology Parathyroid Hormone-Related Protein / blood Proteins Bone Density Conservation Agents PTHLH protein, human Parathyroid Hormone-Related Protein Proteins Denosumab Calcium Humoral Hypercalcemia Of Malignancy
PMC5216142
27904108
Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma
2016